Immodulon is led by a core management team of highly experienced practitioners and drug development experts, and supported by a Board of Directors with both medical & commercial expertise. Immodulon’s Scientific Advisory Board is made up of some of the leading names in immunology and oncology drug development.
Bio Elpida, the company-owned R&D and manufacturing capability in Lyon, France, provides specialist resources to advance the technology platform, including the potential to develop a variety of heat-killed mycobacterial products, as required to meet clinical and commercial needs. Immodulon is planning to expand production and development facilities by establishing a second laboratory outside France in a location to be decided.
Immodulon is an independent company, funded by private individual investors and with its own strategic control. It is philanthropic in its broader aims, committed to producing treatments that are widely affordable.